IN THE NEWS: Ira Winer, M.D., Ph.D., Discusses Next Steps for Nemvaleukin Alfa Plus Pembrolizumab in Ovarian Cancer


Ira Winer, M.D., Ph.D., FACOG, member of the Gynecologic Oncology and Phase I Clinical-Pharmacology Multidisciplinary Teams at Karmanos, spoke about the future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated resistant ovarian cancer.

Listen to his interview with CancerNetwork here.